In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni enter strategic partnerships, secure new funds, announce reimbursement wins, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).
Formed a strategic partnership with CD Biopharma to accelerate the development of precision immunotherapy-based drugs for solid tumors using its Carbon Mirror™ platform. The technology enables drug testing in silico and charts the optimal route to success across tumor types, regions, geographies, and communities of people.
Announced a three-way collaboration with Myriad Genetics and MagView to deliver the first integrated AI and genetic risk platform for personalized breast health. The partnership combines image-based risk from Clairity Breast, hereditary and polygenic insights from Myriad’s MyRiskⓇ with RiskScoreⓇ, and the workflow infrastructure of MagView’s Luminary Risk platform.
Completed a $10M Series A to accelerate global expansion of its flexible MRI coil technology. The raise follows FDA clearance of its 3T Philips-compatible coil, now giving InkSpace full multi-OEM compatibility across Philips, Siemens Healthineers, and GE HealthCare MRI systems.
Announced a partnership with US ENT Partners to expand access to its ArthroFreeⓇ Wireless Camera System across ENT practices nationwide. The partnership supports Lazurite’s mission to modernize minimally invasive procedures with cable-free technology that improves workflow, safety, and patient experience.
Earned a major reimbursement milestone as CMS finalized significantly higher 2026 outpatient and ASC facility payment rates for the GenioⓇ hypoglossal nerve stimulation implant under CPT code 64568. The updated rates strengthen the company’s U.S. expansion strategy by supporting broader therapy adoption across Medicare-heavy institutions.
Announced that the RADIANCE CED study received CMS approval, satisfying the Coverage with Evidence Determination (CED) requirement for the recent National Coverage Determination on renal denervation. The study will collect real-world data and build on the existing safety and efficacy evidence for its ParadiseⓇ uRDN system.
Announced the launch of its second impact fund, BSocial Impact Fund II, which will have a target size of €80M. The new vehicle is the largest of its kind in Spain dedicated to impact projects, and its mission is to invest in startups that improve the quality of life of vulnerable groups and the elderly or contribute to the decarbonization of industry and the regeneration of ecosystems.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy